143results about How to "Minor side effects" patented technology

Disclosed are oral compositions comprising a stannous ion source, a polyvalent cation source and a mineral surface active agent, said compositions providing enhanced therapeutic efficacy derived from stannous fluoride and/or other stannous salt, including antimicrobial effects, control of breath malodor, control of dental plaque growth and metabolism, reduced gingivitis, decreased progression to periodontal disease, reductions in dentinal hypersensitivity and reduced coronal and root dental caries. The aforementioned benefits are provided along with significant improvements compared to conventional stannous containing compositions, including: 1) reduced levels of dental staining; 2) reduced astringency thereby improving aesthetic characteristics of the compositions; 3) reduction in dental calculus formation, and 4) enhanced stability, bioavailability and thus, efficacy of stannous. The mineral surface active agents are agents that are substantive to mineral surfaces such as teeth and have chelating activity for polyvalent cations including stannous (Sn⁺²), zinc (Zn⁺²), copper (Cu⁺²), aluminum (Al⁺²), iron (Fe⁺², Fe⁺³), strontium (Sr⁺²), calcium (Ca⁺²), barium (Ba⁺²), magnesium (Mg⁺²), and manganese (Mn⁺²). Preferred mineral surface-active agents include polymers or copolymers containing phosphate, phosphonate, or carboxy groups. The compositions may also comprise a fluoride ion source and may be formulated as single phase or dual phase compositions.

Disclosed are improvements in human nutrition involving a unique combination of natural products constituting anti-inflammatory compositions which can reduce cardiovascular disease risks as well as play a positive role in other conditions and diseases for which key indicators, especially selected from the group consisting of C-reactive protein (CRP) levels, cyclooxygenase-2 (COX-2), 5-lypoxygenase (5-LOX) expression and prostaglandin E2 (PGE-2) biosynthesis or any combination of these, are indicators. Therapeutic compositions preferably comprise curcumin, bilberry extract, grape seed extract, green tea extract and apple extract, in effective amounts individually and combined to provide a therapeutically significant reduction in one or more key indicators. Another exemplified therapeutic composition comprises: omega-3 rich refined fish oil, resveratrol, blueberry extract, grape seed extract, green tea extract and gamma and/or delta tocopherol, in effective amounts individually for the above benefits.

The present invention relates to novel methods for identifying antiviral agents which selectively interfere with viral proteins that override the interferon(IFN)-induced cellular defense mechanisms against viral infection. In particular, the present invention relates to screening assays that identify agents which selectively inhibit the interaction between viral proteins containing an interferon sensitivity determining region (ISDR) and IFN-induced PKR protein kinase. The present invention more particularly relates to screening assays that identify agents which selectively inhibit the interaction between hepatitis C virus (HCV) nonstructural 5A protein (NS5A), which contains an ISDR, and IFN-induced PKR protein kinase. The interaction between the viral ISDR and IFN-induced PKR protein kinase results in the override of IFN-induced cellular defense mechanisms to combat viral infection. Therefore the agents identified using the assays of the invention may have utility as antiviral agents.

A method for increasing the hardness of silica/rubber mixtures is disclosed wherein the method comprises blending with said mixture at least one silane and a hardness-increasing amount of at least one member selected from the group consisting of thixotropic fumed silica; precipitated silica; an MQ resin wherein Q is SiO_4/2, M is R¹R²R³SiO_1/2, and R¹, R², and R³ are the same or different functional or non-functional organic groups; carbon black; a thermoplastic resin; and a thermosetting resin.

Aspirin triggered lipid mediators (ATLMs) are disclosed which are useful for the treatment of prevention of inflammation associated with various diseases, including ischemia.

The present invention provides a composition of transdermally administered alkaloids from aconitum plant for ameliorating pain and inflammation. In one aspect, an aconitum alkaloid is delivered in a sufficient amount to achieve and maintain a blood plasma aconitum alkaloid level of about 0.5 ng/mL to about 400 ng/mL. Aconitum alkaloids may be delivered by themselves, or in combination with other elements, such as additional analgesics, other drugs, or positive health promoting substances. Various formulations for the transdermal delivery of aconitum alkaloids are disclosed, and may include selected penetration enhancers.

Methods and devices for the non-thermal, electrically-induced temporary or permanent closure of blood vessels. The subject methods and devices employ pulsed electrical energy according to a defined regime to effect controlled occlusion of targeted blood vessels without heating the vessel and with minimal damage to adjacent tissue. The extent of vessel closure, i.e., temporary (vasoconstriction) or permanent (thrombosis), is controlled based on the manipulation of various parameters of the electrical stimulation regime as well as the configuration of the electrodes used to apply the regime.

The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.

Certain example embodiments relate to techniques for controlling the development of a software application. The system includes an event channel for receiving at least one event that indicates an action performed by one of a plurality of existing development tools used in the development of the software application, a policy-based event engine for evaluating the at least one event and for initiating at least one action of one of the plurality of existing development tools in accordance with at least one policy, and a repository, for storing at least one artifact to define an architecture of the software application. The at least one artifact corresponds to a component of the software application and/or to a dependency between a first component and a second component of the software application.

The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.

A therapeutic composition of lorazepam and its pharmaceutically acceptable derivatives are provided for intranasal administration of at least one predetermined volumetric unit dose in the form of a spray by means that delivers one or more therapeutically prescribed unit doses that are highly accurate as to the volume discharged and which leave no significant quantity of the composition in the delivery means.

Arachidonic acid and/or compounds containing arachidonic acid as a constituent fatty acid are used to obtain compounds which prevent decline of, improve or enhance normal responses of cognitive abilities of a healthy person, and which are highly suitable for pharmaceuticals as well as food products, with minimal side effects.